Glaukos (NYSE:GKOS) COO Joseph Gilliam Sells 10,498 Shares

by · The Cerbat Gem

Glaukos Corporation (NYSE:GKOS – Get Free Report) COO Joseph Gilliam sold 10,498 shares of the company’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $127.68, for a total value of $1,340,384.64. Following the transaction, the chief operating officer directly owned 92,366 shares in the company, valued at approximately $11,793,290.88. This represents a 10.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Glaukos Stock Up 3.6%

NYSE:GKOS traded up $4.31 during trading hours on Monday, reaching $124.29. The company’s stock had a trading volume of 872,424 shares, compared to its average volume of 736,399. The company has a market capitalization of $7.14 billion, a P/E ratio of -80.71 and a beta of 0.67. The stock has a 50 day moving average price of $111.25 and a two-hundred day moving average price of $96.29. Glaukos Corporation has a 12 month low of $73.16 and a 12 month high of $161.78. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.47 and a current ratio of 5.20.

Glaukos (NYSE:GKOS – Get Free Report) last issued its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.11. Glaukos had a negative return on equity of 7.52% and a negative net margin of 18.65%.The company had revenue of $133.54 million during the quarter, compared to analysts’ expectations of $122.55 million. During the same quarter in the previous year, the firm posted ($0.28) EPS. The firm’s revenue was up 38.1% compared to the same quarter last year. Equities analysts predict that Glaukos Corporation will post -1.08 EPS for the current fiscal year.

Institutional Trading of Glaukos

Large investors have recently added to or reduced their stakes in the business. Norges Bank bought a new stake in shares of Glaukos in the 2nd quarter valued at approximately $76,314,000. Primecap Management Co. CA boosted its stake in Glaukos by 50.0% in the 2nd quarter. Primecap Management Co. CA now owns 1,827,998 shares of the medical instruments supplier’s stock valued at $188,814,000 after buying an additional 609,523 shares in the last quarter. Alliancebernstein L.P. grew its position in Glaukos by 38.5% in the third quarter. Alliancebernstein L.P. now owns 1,733,474 shares of the medical instruments supplier’s stock valued at $141,365,000 after acquiring an additional 481,620 shares during the period. AustralianSuper Pty Ltd acquired a new position in Glaukos during the second quarter worth $41,946,000. Finally, William Blair Investment Management LLC raised its stake in Glaukos by 52.4% during the second quarter. William Blair Investment Management LLC now owns 1,136,095 shares of the medical instruments supplier’s stock worth $117,347,000 after acquiring an additional 390,805 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on GKOS shares. Stephens boosted their target price on shares of Glaukos from $115.00 to $145.00 and gave the stock an “overweight” rating in a research note on Friday, January 2nd. Needham & Company LLC reaffirmed a “buy” rating and set a $125.00 price objective on shares of Glaukos in a report on Wednesday, January 14th. UBS Group upped their target price on Glaukos from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, December 23rd. Truist Financial lifted their price target on shares of Glaukos from $120.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Finally, Wells Fargo & Company upped their price objective on shares of Glaukos from $120.00 to $122.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $131.38.

Check Out Our Latest Analysis on Glaukos

About Glaukos

(Get Free Report)

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.

Featured Stories